Sanofi (SNYNF)
OTCMKTS · Delayed Price · Currency is USD
96.64
-5.36 (-5.25%)
Oct 8, 2025, 12:59 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 45.74B, up 15.65% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B EUR
Revenue Growth
+15.65%
P/S Ratio
2.24
Revenue / Employee
551.87K EUR
Employees
82,878
Market Cap
120.50B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |
Sanofi News
- 1 day ago - Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
- 1 day ago - Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
- 1 day ago - Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus
- 2 days ago - AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga
- 3 days ago - Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) - Seeking Alpha
- 5 days ago - Bullish Two Hundred Day Moving Average Cross - SNY - Nasdaq
- 6 days ago - Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay - GuruFocus
- 6 days ago - Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - Business Wire